Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Products under Development by Stage of Development | 8 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Products under Development by Therapy Area | 9 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Products under Development by Indication | 10 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Products under Development by Companies | 13 | 2 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Products under Development by Universities/Institutes | 15 | 2 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Companies Involved in Therapeutics Development | 23 | 8 |
| AMO Pharma Limited | 23 | 1 |
| Angelini Group | 24 | 1 |
| Celon Pharma Sp. z o.o. | 25 | 1 |
| DiaMedica Inc. | 26 | 1 |
| HitGen LTD | 27 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 28 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 29 | 1 |
| Neurim Pharmaceuticals Ltd | 30 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Drug Profiles | 31 | 19 |
| CPL-202100 Drug Profile | 31 | 1 |
| DM-199 Drug Profile | 32 | 4 |
| DM-204 Drug Profile | 36 | 2 |
| Drug to Inhibit GSK3-Beta for Alzheimer's Disease Drug Profile | 38 | 1 |
| IB-AD Drug Profile | 39 | 1 |
| JGK-263 Drug Profile | 40 | 1 |
| manzamine A Drug Profile | 41 | 1 |
| Neu-120 Drug Profile | 42 | 1 |
| Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies Drug Profile | 43 | 1 |
| Small Molecule to Inhibit GSK3b for Type 2 Diabetes Drug Profile | 44 | 1 |
| Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease Drug Profile | 45 | 1 |
| Small Molecules to Inhibit GSK-3 Beta for CNS Disorders Drug Profile | 46 | 1 |
| Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases Drug Profile | 47 | 1 |
| Small Molecules to Inhibit GSK3 Beta for Type 2 Diabetes, Oncology and Alzheimer s Disease Drug Profile | 48 | 1 |
| tideglusib Drug Profile | 49 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Dormant Projects | 50 | 2 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Discontinued Products | 52 | 1 |
| Glycogen Synthase Kinase 3 Beta (GSK-3 Beta or EC 2.7.11.26) Featured News &Press Releases | 53 | 7 |
| Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia | 53 | 1 |
| Nov 04, 2015: DiaMedica Provides Corporate Update | 53 | 1 |
| Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference | 54 | 1 |
| Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases | 55 | 1 |
| Nov 17, 2014: DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes | 55 | 1 |
| Aug 07, 2014: DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes | 55 | 1 |
| Jun 10, 2014: DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference | 56 | 1 |
| Feb 19, 2014: DiaMedica announces successful completion of Phase 1 program for DM199 | 56 | 1 |
| Jan 09, 2014: DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients | 56 | 1 |
| Sep 30, 2013: DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients | 57 | 1 |
| Aug 20, 2013: DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study | 58 | 1 |
| Jun 24, 2013: DiaMedica Advances DM-199 Phase I/II Clinical Program For Treatment Of Type 2 Diabetes | 58 | 1 |
| Jun 20, 2013: Sanford Project &DiaMedica To Present Preclinical Abstract on DM-199 For Treatment Of Type 1 Diabetes At 73rd Annual ADA Conference | 58 | 1 |
| May 01, 2013: DiaMedica Initiates Phase I/II Clinical Trial Of DM-199 For Treatment Of Type 2 Diabetes | 59 | 1 |
| Apr 08, 2013: DiaMedica Receives Phase I/II Clinical Trial Regulatory Approval For DM-199 As Potential Treatment For Diabetes | 59 | 1 |
| Appendix | 60 | 2 |
| Methodology | 60 | 1 |
| Coverage | 60 | 1 |
| Secondary Research | 60 | 1 |
| Primary Research | 60 | 1 |
| Expert Panel Validation | 60 | 1 |
| Contact Us | 60 | 1 |
| Disclaimer | 61 | 1 |